- Home
- GDO vs ASRT Comparison
GDO vs ASRT Comparison
Compare GDO & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GDO | ASRT |
|---|---|---|
| Founded | 2009 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.4M | 75.1M |
| IPO Year | N/A | 1997 |
Fundamental Metrics
Financial Performance| Metric | GDO | ASRT |
|---|---|---|
| Price | $11.51 | $11.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | 39.4K | ★ 51.7K |
| Earning Date | 01-01-0001 | 03-11-2026 |
| Dividend Yield | ★ 9.81% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $137,354,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 9.22 |
| 52 Week Low | $11.21 | $7.71 |
| 52 Week High | $13.04 | $15.15 |
Technical Indicators
Market Signals| Indicator | GDO | ASRT |
|---|---|---|
| Relative Strength Index (RSI) | 40.33 | 74.89 |
| Support Level | $11.55 | $11.35 |
| Resistance Level | $11.71 | $12.54 |
| Average True Range (ATR) | 0.11 | 0.73 |
| MACD | -0.01 | -0.25 |
| Stochastic Oscillator | 24.14 | 77.43 |
Price Performance
Historical ComparisonAbout GDO Western Asset Global Corporate Defined Opportunity Fund Inc.
Western Asset Global Corp Defined Opp is a closed-end management investment company with a primary investment objective to provide current income. Its secondary objective is to seek capital appreciation. The Fund invests in the United States and foreign corporate fixed-income securities of varying maturities.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.